Jewish General Hospital

2016 is the inaugural OneWalk to Conquer Cancer benefiting the Segal Cancer Centre at the Jewish General Hospital.

Funds raised through OneWalk to Conquer Cancer support Personalized Cancer Medicine including life-saving cancer research, treatment, care and prevention programs for all cancers at the Jewish General Hospital’s Segal Cancer Centre in Montreal.

The Jewish General Hospital’s Segal Cancer Centre is a leader in Quebec in implementing a focused and comprehensive approach to fighting cancer through a combination of medical treatment, patient care, family support and scientific research. The centre is one of few in the world which offers a combination of strong research and highly skilled clinicians under one roof.

The world-leading doctors, researchers and scientists at the Jewish General Hospital are working to develop new technologies in the areas of Personalized Cancer Medicine, molecular diagnostics, functional imaging, biomarkers, molecular target discovery and validation, and advanced targeted radiation therapy.

Since 2005, supporters of the Jewish General Hospital have been walking and riding to help conquer cancer in all its forms.

In 11 years, the Pharmaprix Weekend to End Women’s Cancers raised nearly $60 million for the Jewish General Hospital.

When a participant registers for OneWalk, they can select which cancer fund their dollars raised will support. OneWalk Cancer Funds include: Innovation Cancer Fund Personalized Cancer Medicine; Breast & Gynaecologic Cancers; Genitourinary Cancer including Prostate Cancer; Head & Neck Cancers; Lung Cancer; Hematologic Cancers Including Leukemia & Lymphoma; Gastrointestinal Cancers; Skin Cancer; Adolescents & Young Adults Oncology Program; Cancer Nutrition & Rehabilitation Program.

Funds raised through OneWalk are put to use immediately to attract and retain world-leading doctors, scientists and researchers to implement the most promising cancer research programs and treatments including:

  • Dr. Nathalie Johnson’s research focusing on determining the genetic abnormalities that are associated with a poor response to chemotherapy in lymphoma, especially in adolescent and young adult patients.
  • Dr. Ivan Topisirovic’s studies into the changes in mRNA metabolism and protein synthesis in cancer
  • Dr. Frank Bladou’s use of High Intensity Focal Ultrasound in the treatment of prostate cancer.
  • Dr. Michael Witcher’s study of the fundamental aspects of gene regulation which could lead to new approaches in cancer treatments.
  • Dr. Celia Greenwood’s work in in biostatistics and big data that is invaluable to the work of her clinical peers.

Funds raised through OneWalk will also power other core cancer areas at the Jewish General Hospital including:


  • Supporting the Molecular Pathology Centre
  • Studying the tumour microenvironment
  • Acquiring specialized equipment such as confocal spinning disk microscope and a flow cytometry unit that allow researchers to further their studies.
  • Examining gene signatures of breast cancer to identify those at highest risk of developing brain metastasis of breast cancer.


  • Identifying blood “biomarkers” that will identify which patients are most likely to respond to a particular therapy, to avoid giving an ineffective and potentially toxic treatment. This will allow us to provide more customized treatments.
  • Developing clinical drug trials


  • Supporting the nurse navigator program
  • Supporting the Cancer Nutrition Rehabilitation program


  • Supporting research into hereditary cancers.